Why the Aroa Biosurgery (ASX:ARX) share price is lifting today

The Aroa Biosurgery Ltd (ASX: ARX) share price is up 5.7% after the company shared its new product Myriad Morcells has received FDA clearance.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Aroa Biosurgery Ltd (ASX: ARX) share price is up 2.6% after the company shared positive news this morning. A new product from the soft-tissue regeneration company has received US Food and Drug Administration (FDA) clearance.

At the time of writing, the Aroa Biosurgery share price is trading at $1.17 after reaching an intraday high of $1.22 this morning.

Let's look closer at the news of Aroa Biosurgery's newest FDA cleared product.

Myriad Morcells

The company's new product, Myriad Morcells, works to "kick start" a wound's healing, according to Aroa Biosurgery vice president of research and clinical development Dr Barnaby May.

Myriad Morcells uses the Aroa ECM bioscaffold technology and is a powdered version of the company's successful Myriad Matrix, a highly perforated, multi-layered extracellular matrix (ECM) graft.

The company advised that earlier pre-clinical studies showed the Aroa ECM technology included more than 150 components that help repair wounds and blood vessel formations, as well as attracting stems cells.

According to Aroa Biosurgery, the use of Myriad Matrix may lead to faster healing, recovery and hospital discharge for patients. It's designed to have a high volume and surface area with interstitial spaces that cells can easily and rapidly access.

Myriad Matrix received FDA clearance in 2017, with the first sales taking place in early 2020. Aroa Biosurgery says the product has an estimated global market size of US$350 million. In mid-2020, it was approved for commercial use in the European Union.

Aroa has six product families based on its ECM technology approved for sale in the United States. Together, they have been used in more than 4 million procedures for chronic wounds, hernia, soft tissue and breast reconstruction.

Commentary from management

Aroa Biosurgery founder and CEO Brian Ward said the company was pleased with its progress in growing the Myriad portfolio, saying:

This clearance for Myriad Morcells follows closely on studies showing positive clinical outcomes from the use of Myriad Matrix on exposed vital structures, in surgical treatment of serious cases of the inflammatory skin condition hidradenitis suppurativa and in reconstruction of complex non-healing wounds.

Aroa Biosurgery share price snapshot

Today's news comes at a good time for the Aroa Biosurgery share price, which is having a slow year on the ASX. It is currently up 5.7% year to date, having ended Thursday's trading back at its 2021 starting price.

However, shares in the company have dropped 10.7% over the last 12 months.

Aroa Biosurgery has a market capitalisation of around $342 million, with approximately 300 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »